CSE$NVO

Novo Nordisk B A/S · Q3 2014 earnings

Q3 2014 earnings · · Investor relations

Headline financials

Total Revenue

kr3.77B

Previous: kr3.67B+2.8%
EPS (adj)

kr0.21

Previous: kr0.05+320.0%

Revenue & EPS history

Novo Nordisk · Revenue · Quarterly

kr3.77B

Q3 2014+2.8%vs Q3 2013
Beat estimate in 6 of 9 quarters(67%)
ActualEstimate

Revenue by segment

Novo Nordisk · kr272B total across 1 segment · Q4 2024

  • Diabetes and Obesity care
    kr272B

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports

Historical avg

+31.7%

Avg return

Earnings day

+14.7%

Avg return

5 days after

+14.1%

Avg return

30 days after

50%

24 / 48 earnings

Positive

+597.3%

Q1 2025

Best reaction

-13.9%

Q2 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+556.0%+569.8%+533.1%
Q3 2025-4.4%-4.8%-0.8%
Q1 2025+597.3%+3.0%+9.0%
Q4 2024+2.2%+1.6%+5.5%
Q3 2024-0.2%-0.9%+0.6%
Q2 2024-2.2%-0.2%+0.8%
Q1 2024-3.9%-1.5%+4.7%
Q3 2023+1.6%+4.1%+2.8%
Q2 2023-2.9%-1.3%+4.2%
Q1 2023-3.7%+0.5%-6.3%
Q4 2022-5.1%-0.5%+4.4%
Q3 2022+2.4%+8.1%+19.2%
Q2 2022-9.1%-10.5%-10.7%
Q1 2022+3.7%+3.4%-2.2%
Q4 2021+4.9%-0.8%+1.5%
Q3 2021+3.9%+4.2%-2.7%
Q2 2021+0.3%+1.9%+2.7%
Q1 2021+2.7%+2.9%+9.2%
Q4 2020+1.1%-0.1%-1.9%
Q3 2020-5.1%+5.5%+1.8%
Q2 2020-3.3%+0.2%+0.0%
Q1 2020-0.3%+1.3%+2.2%
Q4 2019+4.4%+3.3%+1.6%
Q3 2019+2.3%+2.7%+1.7%
Q2 2019+3.9%+3.2%+3.7%
Q1 2019-2.8%-0.9%-3.4%
Q4 2018+2.7%+3.5%+5.5%
Q3 2018+3.3%-0.1%+8.0%
Q2 2018-5.4%-5.8%-4.5%
Q1 2018+6.9%+0.2%+0.2%
Q4 2017-9.1%-10.8%-8.6%
Q3 2017-0.2%-0.2%+4.4%
Q2 2017+0.0%-2.1%+2.6%
Q1 2017+6.6%+2.0%+11.2%
Q4 2016-8.4%-9.0%-5.5%
Q3 2016-13.6%-13.9%-21.6%
Q2 2016-13.9%+0.6%-20.1%
Q1 2016-1.2%+0.9%-14.4%
Q4 2015+5.0%
Q3 2015-6.0%
Q2 2015-4.5%
Q1 2015+2.8%
Q4 2014-2.8%
Q3 2014+5.7%
Q2 2014-3.5%
Q1 2014+2.5%
Q4 2013+9.5%
Q3 2013+400.0%
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro